Pharmacology and Pharmacokinetics of A Novel Nonpeptide Angiotensin II Receptor Antagonist–DMP 811

References

• Duncia JV, Carini DJ, Chiu AT, Johnson AL, Price WA, Wong PC, Wexler RR, Timmermans P BMW. The M. discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med Res Rev 1992; 12: 149–191
   PubMed Web of Science ®Google Scholar
• Wong PC, Barnes TB, Chiu AT, Christ DD, Duncia JV, Herblin WF, Timmermans P BMWM. Losartan (DuP 753), an orally-active nonpeptide angiotensin II receptor antagonist. Cardiovasc Drug Rev 1991; 9: 317–339
   Google Scholar
• Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans P BMWM. Nonpeptide angiotensin II receptor antagonists. XL. Pharmacology of EXP3174, an active metabolite of DuP 753 - an orally-active antihypertensive agent. J Pharmacol Exp Ther 1990; 255: 211–217
   PubMed Web of Science ®Google Scholar
• Munafo A, Christen Y, Nussberger J, Shum L, Borland RM, Lee RJ, Waeber B, Biollaz J, Brunner H R. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51: 513–521
   PubMed Web of Science ®Google Scholar
• Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemcial efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993; 35: 290–297
   PubMed Web of Science ®Google Scholar
• Wong PC, Hart SC, Chiu AT, Herblin WF, Carini DJ, Smith RD, Wexler R R, Timmermans P BMWM. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist. J Pharmacol Exp Ther 1991; 259: 861–870
   PubMed Web of Science ®Google Scholar
• Chiu AT, Carini DJ, Duncia JV, Leung KH, McCall DE, Price W A, Jr., Wong P C, Smith R D, Wexler R R, Timmermans P BMWM, Chang R SL, Lotti V J. DuP 532: a second generation of nonpeptide angiotensin II receptor antagonists. Biochem Biophys Res Commun 1991; 177: 209–217
   PubMed Web of Science ®Google Scholar
• Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR, Johnson AL, Timmermans P BMW. Identification M. of angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 165: 196–203
   PubMed Web of Science ®Google Scholar
• Wong PC, Price W A, Jr., Chiu A T, Carini D J, Duncia J V, Johnson A L, Wexler R R, Timmermans P BMWM. Nonpeptide angiotensin II receptor antagonists: studies with EXP9270 and DuP 753. Hypertension 1990; 15: 823–834
   PubMed Web of Science ®Google Scholar
• Kenakin T P. Pharmacologic Analysis of Drug-Receptor Interactions. Raven Press, New York 1987; 236–239
   Google Scholar
• Wong PC, Hart SD, Duncia JV, Timmermans P BMWM. Nonpeptide angiotensin II receptor antagonists. XIII. Studies with DuP 753 and EXP3174 in dogs. Eur J Pharmacol 1991; 202: 323–330
   PubMed Web of Science ®Google Scholar
• Agra MA, Huang S M. High-performance liquid chromatographic determination of a potent AII receptor antagonist (DMP 811) in plasma. J Chromatogr Biomed Appl 1993; 620: 205–209
   Google Scholar
• Whitebread S., Mele M., Kamber B., Degasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 163: 284–291
   PubMed Web of Science ®Google Scholar
• Chang RSL, Lotti V J. Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. Mol Pharmacol 1990; 29: 347–351
   Google Scholar
• Timmermans P. B. M. W. M., Wong P. C., Chiu A. T., Herblin W. F., Benfield P., Carini D. J., Lee R. J., Wexler R. R., Saye J. M., Smith R. D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205–251
   PubMed Web of Science ®Google Scholar
• Wong P. C., Hajj-ali A. F. Functional correlates of angiotensin receptor stimulation. Medicinal Chemistry of the Renin-Angiotensin System., P. B. M. W. M. Timmermans, R. R. Wexler. Elsevier Science, Amsterdam 1994; 313–346
   Google Scholar
• Sandberg K. Structural analysis and regulation of angiotensin receptors. Trends Endocrinol Metab 1994; 5: 28–35
   PubMed Web of Science ®Google Scholar
• Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993; 268: 24543–24546
   PubMed Web of Science ®Google Scholar
• Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau V J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993; 268: 24539–24542
   PubMed Web of Science ®Google Scholar
• Lindgren BR, Andersson R GG. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. Med Toxicol Adverse Drug Exp 1989; 4: 369–380
   PubMedGoogle Scholar
• Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans P BMWM. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 726–732
   PubMed Web of Science ®Google Scholar
• Nelson E, Merrill D, Sweet CS, Bradstreet T, Panebianco D, Byyny R, Herman T, Lasseter K, Levy B, Lewis G, Mcmahon FG, Reeves R, Ruff D, Shepherd A, Weidler D, Irvin J. Efficacy and safety of oral MK-954 (DuP 753), an angiotensin receptor antagonist, in essential hypertension. J Hypertens 1991; 9(Suppl 6)S468
   Google Scholar
• Nelson E, Arcuri K, Ikeda L, Snavely D, Sweet C S. Efficacy and safety of losartan in patients with essential hypertension. Am. J. Hypertens 1992; 5(5)19A, Part 2
   Google Scholar
• Goldberg M. R., Bradstreet T. E., McWilliams E. J., Tanaka W. K., Lipert S., Bjornsson T. D., Waldman S. A., Osborne B., Pivadori L., Lewis G., Blum R., Herman T., Abraham P. A., Halstenson C. N., Lo M.-W., Lu H., Spector R. Biochemical effecs of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995; 25: 37–46
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1994; 10: 1093–1095
   Web of Science ®Google Scholar
• Choi YM, Chung SM, Huang SM, Quon CY, Chiou W. L. Permeability and first pass accumulation of AII receptor antagonists DuP 532 and DMP 811 in rat intestinal preparation. presented at the AAPS Ninth Annual Meeting, San Diego, CA, 1994; S406, PPDM 8293. abstract in Pharm. Res. 11, 10
   Google Scholar
• Ribadeneira M, Krauthauser CL, Quon CY, Huang S M. Intestinal absorption of structurally related angiotensin II receptor antagonists (An in vitro study of structure-permeation relationships). presented at Fifth North American International Society for the Study of XenobioticsMeeting, Tucson, AZ, 1993; 54, abstract in Proceedings 4
   Google Scholar